•  
  •  
 

Peer Reviewed

1

Abstract

A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer.

Keywords

Gefitinib; endometrial cancer; epidermal growth factor receptor (EGFR); soluble EGFR; estrogen receptor; progesterone receptor

Total Pages

2

Rights

Copyright © Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robet S. Mannel, Krishnansu S. Tewari, Parviz Hanjan, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle, 2013.

Creative Commons License


This work is licensed under a Creative Commons Attribution 3.0 License.

Share

COinS